Statins and stroke (Q81623503)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815580%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

review article

1 reference

title

Statins and stroke (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815580%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Matthias Endres

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815580%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

1 September 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815580%20AND%20SRC:MED&resulttype=core&format=json

Journal of Cerebral Blood Flow & Metabolism

10 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815580%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815580%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815580%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

1093-1110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815580%20AND%20SRC:MED&resulttype=core&format=json

Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Prior statin therapy is associated with a decreased rate of severe sepsis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Stroke prevention, blood cholesterol, and statins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Simvastatin protects against long-lasting behavioral and morphological consequences of neonatal hypoxic/ischemic brain injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Prophylactic but not delayed administration of simvastatin protects against long-lasting cognitive and morphological consequences of neonatal hypoxic-ischemic brain injury, reduces interleukin-1beta and tumor necrosis factor-alpha mRNA induction, an

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Safety of statins: focus on clinical pharmacokinetics and drug interactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Statin use and stroke outcomes in the Heart and Estrogen-Progestin Replacement Study (HERS).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Statin therapy after acute ischemic stroke in the heart protection study: is the role in recurrent stroke prevention now defined?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces delayed neuronal death following transient forebrain ischemia in the adult rat hippocampus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Beneficial cardiovascular pleiotropic effects of statins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Statin-associated rhabdomyolysis triggered by grapefruit consumption

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Influence of cholesterol on survival after stroke: retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Effects of statins on endothelium and signaling mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Targeting eNOS for stroke protection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: implications for vascular disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Regulation of endothelium-derived nitric oxide production by the protein kinase Akt

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Natural statins and stroke risk.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Withdrawal of statin treatment abrogates stroke protection in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

A gp91phox Containing NADPH Oxidase Selectively Expressed in Endothelial Cells Is a Major Source of Oxygen Radical Generation in the Arterial Wall

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Safety and statin therapy: reconsidering the risks and benefits

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Redox control of vascular smooth muscle proliferation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Lipids and stroke: a paradox resolved

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Withdrawal of statins in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Withdrawal of statins increases event rates in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Structural mechanism for statin inhibition of HMG-CoA reductase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Decrease of endothelial nitric oxide synthase in stroke-prone spontaneously hypertensive rat cerebral cortex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Protective effect of pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, on ischemia-induced neuronal damage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, reduces hippocampal damage after transient cerebral ischemia in gerbils

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Statins as a newly recognized type of immunomodulator

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Clinical significance of the atorvastatin-clopidogrel drug-drug interaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Neuroprotection mediated by changes in the endothelial actin cytoskeleton.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Favorable outcome of ischemic stroke in patients pretreated with statins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Inhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Effects of Statins on Platelet Inhibition by a High Loading Dose of Clopidogrel

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Effect of pitavastatin against expression of S100beta protein in the gerbil hippocampus after transient cerebral ischaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Immunomodulation: a new role for statins?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Mechanistic studies on metabolic interactions between gemfibrozil and statins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Simvastatin inhibits the division and induces neurite-like outgrowth in PC12 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Statin therapy improves cardiovascular outcome of patients with peripheral artery disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Early Withdrawal of Statin Therapy in Patients With Non–ST-Segment Elevation Myocardial Infarction National Registry of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Cerivastatin and reports of fatal rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Ultrastructural characteristics of occluded perforating arteries in stroke-prone spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Atherosclerosis and stroke

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Update on statins: 2003.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Better outcome after stroke with higher serum cholesterol levels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Statins for prevention of stroke

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Pravastatin, blood pressure, and stroke

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Lipid-lowering drugs and the risk of depression and suicidal behavior

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Rising statin use and effect on ischemic stroke outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Long-term statin use and psychological well-being

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JCBFM.9600116

7 January 2021

Identifiers

DOI

10.1038/SJ.JCBFM.9600116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15815580%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference